Compare · ARGX vs QNCX
ARGX vs QNCX
Side-by-side comparison of argenx SE (ARGX) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 2011.3x QNCX ($31.5M).
- Over the past year, ARGX is up 49.1% and QNCX is down 90.1% - ARGX leads by 139.2 points.
- ARGX has been more active in the news (12 items in the past 4 weeks vs 10 for QNCX).
- ARGX has more recent analyst coverage (25 ratings vs 7 for QNCX).
- Company
- argenx SE
- Quince Therapeutics Inc.
- Price
- $1056.31+3.59%
- $31.75-5.24%
- Market cap
- $63.27B
- $31.5M
- 1M return
- +21.19%
- +68.88%
- 1Y return
- +49.13%
- -90.11%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2019
- News (4w)
- 12
- 10
- Recent ratings
- 25
- 7
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx upgraded by UBS with a new price target
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
Latest QNCX
- SEC Form DEF 14A filed by Quince Therapeutics Inc.
- SEC Form EFFECT filed by Quince Therapeutics Inc.
- Craig Hallum initiated coverage on Quince Therapeutics with a new price target
- Quince Therapeutics Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form SCHEDULE 13G/A filed by Quince Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.
- Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
- SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.
- Amendment: SEC Form S-3/A filed by Quince Therapeutics Inc.